How to buy Gilead Sciences stock (GILD)

Gilead Sciences is a biopharmaceutical company headquartered in California. The company is most well-known as the maker of remdesivir, also known as Veklury, an experimental antiviral drug that may help treat the novel coronavirus.

In May, remdesivir was designated for emergency use authorization for treatment of COVID-19 by the U.S. Food and Drug Administration (FDA), which means it's being used to treat patients in emergency situations. While the drug isn't fully approved by the FDA and its efficacy and long-term effects are still being studied, this designation has generated a lot of buzz for Gilead.

Our top picks for where to buy Gilead Sciences stock

Buy Gilead Sciences stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Gilead Sciences stock price (NASDAQ: GILD)

Use our graph to track the performance of GILD stocks over time.

Gilead Sciences shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$91.09
52-week range	$60.24 - $98.08
50-day moving average more info button	$90.12
200-day moving average more info button	$76.71
Wall St. target price	$98.92
PE ratio more info button	1007.6666
Dividend yield more info button	$3.06 (3.4%)
Earnings per share (TTM) more info button	$0.09

Is it a good time to buy Gilead Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Gilead Sciences price performance over time

Historical closes compared with the close of $92.57 from 2024-12-20

1 week (2024-12-13)	0.77%
1 month (2024-11-22)	2.64%
3 months (2024-09-20)	10.28%
6 months (2024-06-21)	30.99%

1 year (2023-12-22)	16.21%
2 years (2022-12-22)	17.35%
3 years (2021-12-22)	44.47%
5 years (2019-12-20)	69.85%

Is Gilead Sciences stock undervalued or overvalued?

Valuing Gilead Sciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Gilead Sciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Gilead Sciences's P/E ratio

Gilead Sciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1008x. In other words, Gilead Sciences shares trade at around 1008x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Gilead Sciences's PEG ratio

Gilead Sciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.5227. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Gilead Sciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Gilead Sciences's EBITDA

Gilead Sciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $13.9 billion.

The EBITDA is a measure of a Gilead Sciences's overall financial performance and is widely used to measure a its profitability.

Gilead Sciences financials

Revenue TTM	$28.3 billion
Operating margin TTM	41.96%
Gross profit TTM	$21.6 billion
Return on assets TTM	11.96%
Return on equity TTM	0.56%
Profit margin	0.45%
Book value	$14.83
Market Capitalization more info button	$113 billion

TTM: trailing 12 months

Gilead Sciences's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Gilead Sciences.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Gilead Sciences's total ESG risk score

Total ESG risk: 22.15

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Gilead Sciences's overall score of 22.15 (as at 12/31/2018) is pretty good – landing it in it in the 31st percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Gilead Sciences is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Gilead Sciences's environmental score

Environmental score: 0.53/100

Gilead Sciences's environmental score of 0.53 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Gilead Sciences's social score

Social score: 12.97/100

Gilead Sciences's social score of 12.97 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Gilead Sciences is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Gilead Sciences's governance score

Governance score: 7.65/100

Gilead Sciences's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Gilead Sciences is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Gilead Sciences's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Gilead Sciences scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Gilead Sciences has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Gilead Sciences Inc was last rated for ESG on: 2019-01-01.

Total ESG score	22.15
Total ESG percentile	30.98
Environmental score	0.53
Environmental score percentile	2
Social score	12.97
Social score percentile	2
Governance score	7.65
Governance score percentile	2
Level of controversy	2

Gilead Sciences share dividends

Dividend payout ratio: 69.53% of net profits

Recently Gilead Sciences has paid out, on average, around 100% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Gilead Sciences shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Gilead Sciences's case, that would currently equate to about $3.06 per share.

Gilead Sciences's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Gilead Sciences's most recent dividend payout was on 29 December 2024. The latest dividend was paid out to all shareholders who bought their shares by 12 December 2024 (the "ex-dividend date").

Have Gilead Sciences's shares ever split?

Gilead Sciences's shares were split on a 2:1 basis on 27 January 2013 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Gilead Sciences shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Gilead Sciences shares which in turn could have impacted Gilead Sciences's share price.

Gilead Sciences share price volatility

Over the last 12 months, Gilead Sciences's shares have ranged in value from as little as $60.2439 up to $98.0756. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gilead Sciences's is 0.192. This would suggest that Gilead Sciences's shares are less volatile than average (for this exchange).

Gilead Sciences overview

Gilead Sciences, Inc. , a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc. ; Merck Sharp & Dohme Corp. ; Pionyr Immunotherapeutics Inc.

Frequently asked questions

null
What percentage of Gilead Sciences is owned by insiders or institutions?
Currently 0.117% of Gilead Sciences shares are held by insiders and 88.398% by institutions. How many people work for Gilead Sciences?
Latest data suggests 18,000 work at Gilead Sciences. When does the fiscal year end for Gilead Sciences?
Gilead Sciences's fiscal year ends in December. Where is Gilead Sciences based?
Gilead Sciences's address is: 333 Lakeside Drive, Foster City, CA, United States, 94404 What is Gilead Sciences's ISIN number?
Gilead Sciences's international securities identification number is: US3755581036 What is Gilead Sciences's CUSIP number?
Gilead Sciences's Committee on Uniform Securities Identification Procedures number is: 375558103